secwatch.observer — SEC 8-K summary
======================================

Issuer:     Larimar Therapeutics, Inc. (LRMR)
CIK:        0001374690
Form:       8-K
Filed at:   2026-06-29T10:33:36+00:00
Accession:  0001193125-26-286780
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Larimar submits BLA module for nomlabofusp accelerated approval; positive open-label data in Friedreich's ataxia
--------------------------------------------------------------------------------

- Submitted first module of rolling BLA to FDA for accelerated approval of nomlabofusp; FDA confirmed existing data appears sufficient.
- Open-label study: 100% (9/9) of participants achieved skin FXN levels >50% of healthy volunteer mean at 1 year.
- Clinical outcomes improved vs natural history: mean 1.0-point mFARS improvement vs 1.6-point worsening at 1 year.
- Safety: anaphylaxis in 10/43 patients; 9 had prior nomlabofusp exposure, 1 no prior; all recovered.
- First patient in confirmatory Phase 3 expected Q3 2026; targeting mid-2027 launch if approved.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1374690/000119312526286780/0001193125-26-286780-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1374690/000119312526286780/lrmr-20260629.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-286780

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer